Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00158743 · ClinicalTrials.gov registry record · Phase 2
Efficacy Study of Digibind for Treatment of Severe Preeclampsia
A Phase 2 study, sponsored by BTG International.
- Completed
- Registry status
- Phase 2
- Development phase
- 51
- Enrollment target
NCT00158743: Completed Phase 2 study, sponsored by BTG International.
NCT00158743 is a Phase 2 study that has completed, run by BTG International. The registered enrollment target is 51 participants, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (62% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00158743, a Phase 2 study, has completed, sponsored by BTG International.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 51 participants
- Enrollment target
Study Summary
The purpose of this study is to determine whether a commercially available anti-digoxin antibody, Digibind, can delay delivery in patients with severe pre-eclampsia. If so, this would allow more time for maternally administered steroids to prevent the development of respiratory complications in premature infants.
Primary Outcome
change from baseline in creatinine clearance measured at 24 to 48 hours, comparing patients who received placebo with those who received digoxin immune fab
Interventions
- DRUG Anti-digoxin antibody (FAB fragment)
- OTHER sodium chloride
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 51 participants |
| Start Date | 2004-02 |
| Est. Completion | 2007-12 |
| Phase | Phase 2 |
What the finished NCT00158743 record still lists
NCT00158743 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 51 participants, a relatively small participant target, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (62% lower).
The record links to 0 conditions, and to 2 interventions - of which Anti-digoxin antibody (FAB fragment) is the first listed.
NCT00158743 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00158743 about?
NCT00158743 is a clinical study titled "Efficacy Study of Digibind for Treatment of Severe Preeclampsia". The purpose of this study is to determine whether a commercially available anti-digoxin antibody, Digibind, can delay delivery in patients with severe pre-eclampsia. If so, this would allow more time for maternally administered steroids to prevent the development of respiratory complications in prem...
What is the current status of trial NCT00158743?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 51 participants. The study started on 2004-02. Estimated completion is 2007-12.
What interventions are being tested in trial NCT00158743?
The interventions under investigation include: Anti-digoxin antibody (FAB fragment) (DRUG), sodium chloride (OTHER).
Who is sponsoring clinical trial NCT00158743?
This trial is sponsored by BTG International, which has 5 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT00158743's enrollment target sits among peer trials
51 1190th of 2000 higher than 806 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02701153 · 51 participants · NA
Phase II Study of 5-Day Hypofractionated Preoperative Radiation Therapy for Soft Tissue Sarcomas: Expansion Cohort
- NCT03663790 · 51 participants · NA
Effects of Gait Retraining on Lower Extremity Biomechanics
- NCT03874052 · 51 participants · Phase 1
Ruxolitinib in Combination With Venetoclax With and Without Azacitidine in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia
- NCT04704661 · 51 participants · Phase 1
Testing the Combination of Two Anti-cancer Drugs, DS-8201a and AZD6738, for The Treatment of Advanced Solid Tumors Expressing the HER2 Protein or Gene, The DASH Trial
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia